Regression between e′ at 60–64 years and SBP and antihypertensive treatment at four time points with further adjustment for covariables
| Model 1 | Model 2 | Model 3 | Model 4 | Model 5 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Independent variable | β (95% CI) | p Value | β (95% CI) | p Value | β (95% CI) | p Value | β (95% CI) | p Value | β (95% CI) | p Value | |
| Age 36 (n=1533) | SBP | −0.006 (−0.014 to 0.002) | 0.125 | −0.006 (−0.014 to 0.002) | 0.122 | −0.001 (−0.009 to 0.007) | 0.855 | −0.002 (−0.010 to 0.006) | 0.619 | 0.000 (−0.008 to 0.008) | 0.931 |
| Age 43 (n=1533) | SBP | −0.006 (−0.013 to 0.002) | 0.128 | −0.005 (−0.012 to 0.002) | 0.171 | 0.002 (−0.067 to 0.010) | 0.598 | 0.001 (−0.007 to 0.008) | 0.816 | 0.000 (−0.009 to 0.008) | 0.959 |
| Age 53 (n=1533) | SBP | −0.011 (−0.017 to −0.006) | <0.001 | −0.010 (−0.016 to −0.005) | <0.001 | −0.005 (−0.011 to 0.001) | 0.084 | −0.004 (−0.010 to 0.002) | 0.157 | −0.002 (−0.006 to 0.009) | 0.694 |
| Age 60–64 (n=1533) | SBP | −0.017 (−0.022 to −0.012) | <0.001 | −0.017 (−0.022 to −0.011) | <0.001 | NR | NR | −0.015 (−0.020 to −0.009) | <0.001 | −0.014 (−0.019 to −0.008) | <0.001 |
| Age 36 | HTT | NR | NR | 0.112 (−0.846 to 1.070) | 0.819 | 0.018 (−0.937 to 0.973) | 0.971 | 0.039 (−0.910 to 0.989) | 0.935 | −0.110 (−1.157 to 0.937) | 0.837 |
| Age 43 | HTT | NR | NR | −0.619 (−1.296 to 0.058) | 0.073 | −0.598 (−1.271 to 0.075) | 0.081 | −0.495 (−1.163 to 0.173) | 0.146 | −0.403 (−1.064 to 0.257) | 0.231 |
| Age 53 | HTT | NR | NR | −0.333 (−0.635 to− 0.032) | 0.030 | −0.331 (−0.630 to −0.032) | 0.030 | −0.296 (−0.598 to 0.006) | 0.054 | −0.230 (−0.533 to 0.073) | 0.136 |
| Age 60–64 | HTT | NR | NR | −0.253 (−0.490 to −0.016) | 0.036 | NR | NR | −0.162 (−0.407 to 0.082) | 0.192 | −0.094 (−0.340 to 0.152) | 0.453 |
Imputed (n=1533 for all models—with valid outcome and SBP at age 60–64 years). The variable β is regression coefficient for e′ versus SBP (mm Hg) or antihypertensive treatment (HTT). Model 1: adjusted for age sex and CRF attended. Model 2: model 1+antihypertensive treatment (HTT) at given age (for SBP) or model 1+SBP at given age (for HTT). Model 3: model 2+SBP at 60–64 years. Model 4: model 3+T2DM+BMI+smoking status+physical activity status. Model 5: model 4+left ventricular mass indexed to body surface area. Numbers of individuals receiving HTT were 51 (2%), 107 (3%), 438 (15%) and 640 (27%) at age 36, 43, 53 and 60–64 years, respectively.
BMI, body mass index; CRF, clinical research facility; NR, not relevant; SBP, systolic blood pressure; T2DM, type 2 diabetes mellitus.